Title: Methods of Reducing an Immune Response
Filed: Oct. 31, 2005
Inventor: Quiming Chu, Genzyme
"The invention relates to methods of reducing an immune response to a transgene product in a mammal by co-administration of a small-interfering ribonucleic acid molecule that temporarily inhibits or reduces transgene expression, wherein the siRNA is administered in an amount, and for a period of time, sufficient to reduce an immune response to the transgene product when it is expressed at therapeutic levels," the patent application's abstract states. "The … invention further relates to methods of administering siRNAs to a mammal to reduce an immune response to an immunogenic protein, such as an enzyme used in enzyme replacement therapy."
Title: In Vivo Inhibition of Hepatitis B Virus
Filed: Sept. 26, 2005
Lead Inventor: David Lewis, Mirus
According to the patent application's abstract, the invention involves a process to "deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs," the abstract states.
Title: MicroRNA Vectors
Filed: June 21, 2005
Lead Inventor: David Loyd Turner, University of Michigan
The invention "relates to gene silencing, and in particular to compositions of microRNA sequences and vectors and to methods of synthesizing such in vitro and in vivo, and to methods of using such to regulate gene expression," the patent application's abstract states.
Title: Detecting RNAi Using SELDI Spectrometry
Filed: Sept.22, 2004
Lead Inventor: Reddy Gurucharan, Ciphergen Biosystems
The invention "relates to the fields of protein expression and molecular biology. In particular, the present invention includes methods for monitoring the levels of polypeptide inhibition caused by inhibitory nucleic acids," the patent application's abstract states.